
Baystreet.ca – Soligenix Trumps Year-End Financials
Soligenix, Inc. (NASDAQ: SNGX) shares lost some steam early Friday, as the company, a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the year ended December 31, 2024. Soligenix reported revenues of…